Background and Purpose: Platelet behavior of Sprague Dawley (SD), Wistar (WI), Wistar-Kyoto (WKY), spontaneously hypertensive (SHR), and stroke-prone spontaneously hypertensive rats (SHRSP) was studied in vivo to evaluate the importance of hypertension-related hemostatic disorders.
pathophysiological conditions enhanced activity of its components can be observed, for example, hyperaggregability of platelets.' An increased activation of platelets implies their intravascular consumption. In this connection diseases such as myocardial infarction, thrombosis, formation of embolisms, or disseminated intravascular coagulation may occur. 2 Arterial hypertension is assumed to be an important risk factor for thrombotic diseases.3 A high incidence of thrombosis in coronary and cerebral arteries observed in patients with hypertension may indicate an enhancement of platelet function in these patients. Enhanced adhesion and aggregation as well as hypoaggregability of platelets from hypertensive patients have been reported. [4] [5] [6] [7] The inconsistency of these results is thought to be due to varying experimental conditions and heterogeneity of the patient groups.
Inbred spontaneously hypertensive rats (SHR) and spontaneously hypertensive stroke-prone rats (SHRSP), See Editorial Comment, page 1533 a substrain of SHR, established in 1963 and 1974, respectively, by Okamoto et al, 8'9 are considered to be animal models related very closely to human hypertension. These animals offer the advantage of investigating hypertension-related alteration in platelet function under controlled and comparable regimens. Activation of platelets of these rat strains has been examined by different authors with inconsistent results regarding hypo-or hyperaggregability. [10] [11] [12] [13] [14] [15] [16] Because most of these results have been obtained from in vitro experiments, different methodology (washed platelet or platelets in plasma, different anticoagulants) may at least partially explain this discrepancy.
It was the aim of our study to describe platelet function of SHRSP by comparing the intravascular reactivity of SHR and SHRSP platelets with platelets in Sprague Dawley (SD), Wistar 
Platelet Counting
Blood was taken via the femoral artery and heparinized (50 IU/mL). After fourfold dilution with CFTPG and sedimentation of the erythrocytes and leukocytes, platelet count in the supernatant was determined using an electronic cell counter (Coulter Counter, Coulter Electric, Krefeld, Germany).
Statistics
Time-dependent shifts of Cl: C2, caused by the injection of platelet-activating drugs, were expressed as lAC1: C2 (%). AC1: C2, mean arterial pressure, and heart rate were expressed as the mean+SEM. Unless otherwise indicated, 10 rats were used in each experiment. Results were compared using Student's t test and Bonferroni corrected t test when multiple comparison was made. Values of P<0.05 indicated statistical significance. The same probability values were used to describe linear correlations.
Results

Preparation of Labeled Platelets and Recovery
The purification and labeling of the platelets of the hypertensive substrains of WKY required a larger amount of blood obtained by cardiac puncture compared with SD. This was due to decreased platelet counts in blood of SHR and SHRSP, because blood gained by cardiac puncture or by catheterization of the femoral artery contained significantly lower platelet counts (Table 1) . Despite the weak cardiovascular side effects of urethane,18 the hypertensive rat strains reacted very sensitively at anesthesia. Mean arterial blood pressure was considerably decreased (Table 1) . No strain-specific differences in heart rates could be detected; heart rates varied from 200 to 330 beats per minute (data not shown).
Rats with SD, all WI substrains exhibited a reduced reaction after injection of ADP and thrombin. This effect was most obvious for ADP in WKY and its hypertensive substrains, whereas the platelets' response to thrombin was only slightly weakened in the WI substrains. Injection of collagen, however, resulted in a pulmonary ---r Simultaneously recorded mean arterial blood pressure and heart rate of WI and SHRSP fell reversibly after injection of ADP and collagen (Fig 3) . In arise from platelet-fibrin emboli that originate from lesions in the carotid arteries or from the heart. 21 Our experiments were conducted to describe platelet function of SHRSP in comparison with related strains to investigate the importance of altered platelet function for stroke in SHRSP. The SD strain was used in the study to describe strain-and substrain-specific variations. Platelets of the WI strain were less sensitive when activated by ADP and thrombin. An enhanced collageninduced platelet activation in WI is gradually lost by breeding WKY and the hypertensive rat substrains. Strain-specific variations in platelet aggregation were also observed by Dwyer and Meyers. 22 The in vivo response of WKY, SHR, and SHRSP platelets to ADP was decreased very similarly in comparison to WI. Whereas ADP is believed to play a key role in the thrombogenesis in SD,23 this activator is less effective on SHR and SHRSP platelets. The discrepancy between our findings of a weakened platelet reactivity in all three WI substrains, in contrast to an effect confined to the hypertensive rats,16,24 is presumably due to problems of in vitro experiments. The use of washed platelets, the concentrations of calcium and fibrinogen, and the anticoagulant used for the preparation of platelet-rich plasma affect platelet aggregation in vitro.2425 Because our assay does not require anticoagulants having physiological calcium and fibrinogen concentrations, the results probably show more accurate information about platelet reactivity in vivo. Thrombin induced platelet activation in WI that was not significantly different from the WI inbred substrains. An impaired calcium-dependent response of the SHR and SHRSP platelets after injection of ADP suggests that mechanisms other than a greater rate of agonistinduced uptake of calcium are involved in platelet activation by thrombin.26 In contrast to other authors,27 Huzoor-Akbar and Anwer28 found that platelets of hypertensive rats exerted a strong response in vitro when stimulated with thrombin.
In accordance with our observations, Yamori et a129 described an attenuated aggregation of SHRSP platelets caused by heterologous collagen. Because of its altered chemical structure, 30 however, vascular collagen of SHRSP may account for a significantly stronger mural thrombus formation induced by laser injury compared with WKY. 31 At an advanced age SHRSP were found to exhibit increased coagulative and decreased fibrinolytic activities in blood vessels, which is consistent with necrotic alterations in the intima that lead to a sustained activation of platelets with degranulation.32 Beside its vasoactive effect, endothelium-derived relaxing factor inhibits platelet aggregation and adhesion to the vessel wall.33
Because vasodilation is impaired in SHR and SHRSP, probably in part mediated by decreased release of endothelium-derived relaxing factor,34 this factor could account for a decreased platelet aggregation resulting from exhaustion of preactivated platelets. Accordingly, an agonist-specific primary platelet dysfunction as well as an exhaustion due to permanent activation could account for the intravascular reaction of labeled platelets. Platelet numbers differing from those of normotensive rats were observed by us and others. 35 They are only partially caused by the consumption of platelets due to vascular lesions, because these changes occur at early hypertensive stages before the appearance of these lesions.24 It remains to be mentioned that the response of labeled SHR and SHRSP platelets to the agonists was probably unrelated to an elevated basal mean arterial pressure, because no correlation between this parameter and the extent of platelet accumulation could be detected. To evaluate the effect of the labeling procedure on the strain-specific pulmonary platelet accumulation, we measured ADP-induced aggregation of WI and SHRSP platelets in freshly prepared suspensions and after labeling with M'Cr. We found a decrease of reactivity in both strains. This effect was thought to be due to the absence of the platelet-protective prostaglandin E1. This metabolite is well suited to prepare platelets for studying pulmonary platelet accumulation because it is rapidly eliminated from the circulation. Its platelet-inhibiting activity, however, disturbs platelet aggregation in vitro. Likewise the reduced aggregability of SHRSP platelets in vitro before and after labeling, as well as aggregation in vivo, makes a SHRSP-specific preactivation and exhaustion during platelet preparation very unlikely. Furthermore, the platelets' response was unrelated to a decreased platelet count, since the same amount of labeled platelets was injected into all animals. Despite a greater shift in AC1 C2 after injection of collagen compared with ADP, both activators produced a similar fall in mean arterial pressure. Because ADP is known to release endothelium-derived relaxing factor,36 an endothelium-dependent vasodilation, as well as a reflexive hypotension resulting from the pulmonary platelet embolization, may contribute to the hypotensive responses.
The observations that WKY, SHR, and SHRSP platelets exhibited the same weakened sensitivity against ADP; the response of SHR and SHRSP platelets to collagen was decreased very similarly, an effect also appearing in WKY; and SHR death is mostly caused by cardiovascular decompensation, whereas SHRSP die mainly from cerebral hemorrhage and infarction24 suggest that, despite altered platelet aggregation, additional factors account for the incidence of stroke in SHRSP. Impaired platelet aggregation as well as reduced platelet counts may enhance the bleeding risk and hence contribute to susceptibility to hemorrhagic strokes. Another possibility of platelets indirectly increasing the risk of stroke-related disorders has to be considered. Platelets are known to produce mediators that could interact with the circulating leukocytes, especially the granulocytes.37 These cells were found to be elevated and spontaneously activated in SHR, increasing with the animals' age.38 On the other hand, we were able to demonstrate an aggregation of rat platelets mediated by activated granulocytes.39 Accordingly, a mutual activation of platelets and granulocytes together with an impaired endothelial function might contribute to an enhanced risk for vascular injury in SHRSP. We conclude that a platelet reactivity depending strongly on the experimental design described above offers the opportunity to study special aspects of an altered platelet function. However, it makes it more difficult to evaluate antiplatelet drugs in the primary or secondary prevention of stroke in patients. According to our experiments, comparative investigations with SHR or SHRSP platelets should also include WI platelets.
Editorial Comment
T he convergence of two lines of research makes the study by Klee 
